Khaled Saad

Prof. Dr. Khaled Saad

Pediatrics, Assiut University Hospitals, Assiut, Egypt
+1
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2017 in Nutritional Neuroscience
Verified
Journal Article
Closed access
SSSanaa Y. Shaaban
Sanaa Y. Shaaban
YGYasmin G. El Gendy
Yasmin G. El Gendy
NMNayra S. Mehanna
Nayra S. Mehanna
WEWaled M. El-Senousy
Waled M. El-Senousy
HEHowaida S. A. El-Feki
Howaida S. A. El-Feki
OEOsama El-Asheer
Osama El-Asheer
Objective: There are limited data on the efficacy of probiotics in children with ASD, therefore, this study aims to evaluate the efficacy and tolerability of probiotics in an Egyptian cohort of children with ASD. Methods: Gastrointestinal (GI) flora were assessed by quantitative real-time PCR of stool samples of 30 autistic children from 5 to 9 years old. GI symptoms of autistic children were assessed with a modified six-item Gastrointestinal Severity Index (6-GSI) questionnaire, and autistic symptoms were assessed with Autism Treatment Evaluation Checklist (ATEC) before and after 3 months of supplementation of probiotics nutritional supplement formula (each gram contains 100 × 106 colony forming units of three probiotic strains; Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacteria longum). Results: After probiotic supplementation, the stool PCR of autistic children showed increases in the colony counts of Bifidobacteria and Lactobacilli levels, with a significant reduction in their body weight as well as significant improvements in the severity of autism (assessed by the ATEC), and gastrointestinal symptoms (assessed by the 6-GSI) compared to the baseline evaluated at the start of the study. Conclusions: We concluded that probiotics have beneficial effects on both behavioral and GI manifestations of ASD. Probiotics (a non-pharmacological and relatively risk-free option) could be recommended for children with ASD as an adjuvant therapy. At this stage, this study is a single center with a small number of patients and a great deal of additional wide-scale randomized controlled trials are needed to critically confirm the efficacy of probiotics in ASD. Trial registration number: UMIN-CTR Study Design: Trial Number UMIN000026157

5 February 2020 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
Geir BjørklundGeir Bjørklund
Geir Bjørklund
NMNagwa A. Meguid
Nagwa A. Meguid
MEMona A. El-Bana
Mona A. El-Bana
ATAlexey A. Tinkov
Alexey A. Tinkov
Khaled SaadKhaled Saad
Khaled Saad
Salvatore ChirumboloSalvatore Chirumbolo
Salvatore Chirumbolo

15 April 2015 in Nutritional Neuroscience
Verified
Journal Article
Closed access
Khaled SaadKhaled Saad
Khaled Saad
AAAhmed A. Abdel-Rahman
Ahmed A. Abdel-Rahman
YEYasser M. Elserogy
Yasser M. Elserogy
AAAbdulrahman A. Al-Atram
Abdulrahman A. Al-Atram
JCJohn J. Cannell
John J. Cannell
AAAhmed M. Ali
Ahmed M. Ali
Autism spectrum disorder (ASD) is a developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and non-verbal communication, and stereotyped patterns of interests and activities. Vitamin-D deficiency was previously reported in autistic children. However, the data on the relationship between vitamin D deficiency and the severity of autism are limited. We performed a case-controlled cross-sectional analysis conducted on 122 ASD children, to assess their vitamin D status compared to controls and the relationship between vitamin D deficiency and the severity of autism. We also conducted an open trial of vitamin D supplementation in ASD children. Fifty-seven percent of the patients in the present study had vitamin D deficiency, and 30% had vitamin D insufficiency. The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism. Serum 25-OHD levels had significant negative correlations with Childhood Autism Rating Scale (CARS) scores. Of the ASD group, 106 patients with low-serum 25-OHD levels (<30 ng/ml) participated in the open label trial. They received vitamin D3 (300 IU/kg/day not to exceed 5000 IU/day) for 3 months. Eighty-three subjects completed 3 months of daily vitamin D treatment. Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span. Vitamin D is inexpensive, readily available and safe. It may have beneficial effects in ASD subjects, especially when the final serum level is more than 40 ng/ml. UMIN-CTR Study Design: trial Number: R000016846.

1 January 2016 in Acta Neurobiologiae Experimentalis
Verified
Journal Article
Open access
Geir BjørklundGeir Bjørklund
Geir Bjørklund
Khaled SaadKhaled Saad
Khaled Saad
Salvatore ChirumboloSalvatore Chirumbolo
Salvatore Chirumbolo
JKJanet K. Kern
Janet K. Kern
DGDavid A. Geier
David A. Geier
MUMauricio A. Urbina
Mauricio A. Urbina
Autism spectrum disorder (ASD) is a complex heterogeneous neurodevelopmental disorder with a complex pathogenesis. Many studies over the last four decades have recognized altered immune responses among individuals diagnosed with ASD. The purpose of this critical and comprehensive review is to examine the hypothesis that immune dysfunction is present more frequently, and it is related to ASD in humans. It was found that that often individuals diagnosed with ASD have alterations in immune cells such as T cells, B cells, monocytes, natural killer cells, and dendritic cells. Also, many individuals diagnosed with ASD have alterations in immunoglobulins and increased autoantibodies. Finally, an important portion of individuals diagnosed with ASD has elevated peripheral cytokines and chemokines and associated neuroinflammation. In conclusion, immune dysregulation and inflammation are important components of ASD diagnosis and are key components of the diagnosis and treatment of ASD.

14 August 2017 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
OEOmnia El-Rashidy
Omnia El-Rashidy
FEFarida El-Baz
Farida El-Baz
YEYasmin El-Gendy
Yasmin El-Gendy
RKRanda Khalaf
Randa Khalaf
DRDina Reda
Dina Reda
Khaled SaadKhaled Saad
Khaled Saad

21 November 2016 in Journal of Child Psychology and Psychiatry
Verified
Journal Article
Closed access
PDF file
Khaled SaadKhaled Saad
Khaled Saad
AAAhmed A. Abdel‐Rahman
Ahmed A. Abdel‐Rahman
YEYasser M. Elserogy
Yasser M. Elserogy
AAAbdulrahman A. Al‐Atram
Abdulrahman A. Al‐Atram
AEAmira A. El‐Houfey
Amira A. El‐Houfey
AAAhmad M. Abdel‐Salam
Ahmad M. Abdel‐Salam